Described by patients as “life changing”, this new device treats the underlying causes of erectile dysfunction, bringing spontaneity and privacy back to the bedroom.
WESTFORD, Mass., November 1, 2021 / CNW / – Cynosure, the world leader in medical aesthetics, today announced the Canadian launch of its ViaSure device to effectively treat the underlying causes, not just the symptoms, of erectile dysfunction in vascular origin. Powered by patented SoftWave ™ technology, the ViaSure treatment safely and effectively increases blood flow and restores smooth muscle cells to treat erectile dysfunction in men. ViaSure treatment is a safe, effective and non-invasive alternative to traditional medications typically used to temporarily treat problems with sexual performance. With ViaSure treatments, there are no pills, no surgery and no downtime.
“Studies show that 50 percent of men over 50 will suffer from erectile dysfunction,” said Todd Tillemans, Managing Director of Cynosure. With the ViaSure device, providers can safely and effectively treat the underlying causes of vascular erectile dysfunction, helping to build self-confidence. This is a game-changer for men’s physical and emotional health, and we look forward to introducing our science-based technology to a new audience of vendors backed by leading experts. “
The ViaSure System is the only men’s sexual health device featuring exclusive SoftWave ™ technology with a uniquely designed applicator to ensure optimal and consistent coverage and depth of shockwave energy. Upon delivery of shock wave energy, a cellular response is triggered, activating the body’s natural healing process, forming new blood vessels to increase blood flow and proliferation of smooth muscle cells to restore l elasticity of the tissues in the penis.
“ViaSure has been a great addition to our men’s sexual health treatment offering,” said Dr. Irwin Goldstein, San Diego Sexual Medicine. “My patients have described these treatments as comfortable, fast and life changing.”
The ViaSure device is commercially available in the United States and Canada. To learn more, please visit www.cynosure.com.
Cynosure is the world leader in medical aesthetics and develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other physicians to perform non-invasive and minimally invasive procedures for skin revitalization, l hair removal, body contouring, women’s health, treat vascular and benign pigmented lesions, remove multi-color tattoos, reduce fat by laser lipolysis and reduce cellulite. Cynosure’s product portfolio consists of a wide range of energy sources including Alexandrite, Diode, Nd: YAG, Picosecond, Pulsed Dye, Q-switched lasers, Intense Pulsed Light and RF technology. Cynosure sells its products worldwide under the Cynosure, Palomar, ConBio and Ellman brands through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the UK, Australia, China, Thailand, Japan and Korea, and through international distributors in about 130 other countries. For company or product information, visit the Cynosure website atwww.cynosure.com.
ViaSure is indicated by Health Canada for the treatment of penile dysfunctions such as: Peyronie’s disease – PPI (Induratio penis plastica); erectile dysfunction – ED; chronic pelvic pain (CPP) / chronic prostatitis
Like all medical procedures, not all patients are suitable for treatment. A qualified practitioner is solely responsible for evaluating the suitability of each subject to undergo treatment and for informing those treated of the risks associated with the treatment, pre and postoperative care and any other relevant information. Individual results may vary and are not guaranteed.
© 2021 Cynosure, LLC. All rights reserved. Cynosure, LLC owns the exclusive rights to the photograph. Use of photographs without written permission from Cynosure is prohibited. Cynosure and ViaSure are registered trademarks of Cynosure, LLC. SoftWave is a registered trademark of Tissue Regeneration Technologies, LLC.
SOURCE Cynosure, Inc.